share_log
Reuters ·  May 7 08:53
Neurosense Therapeutics Ltd: Primec Slowed Disease Progression by 43% (P=0.02) in Pre-Specified High-Risk ALS Patients
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment